GlassScriptPhysician profile
Mehul M Patel
NPI 1689931404
$2,294.46
in general payments reported to CMS, 2019-2025
10 companies · $770 in 2025
The $770 reported for 2025 was more than what 81% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $221 · 2020: $27.51 · 2023: $1,178 · 2024: $98.26 · 2025: $770.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $1,923 · Food and Beverage: $124.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $1,922.65 |
| Food and Beverage | $123.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $1,152.77 | 2023 | Corevalve Evolut R |
| Edwards Lifesciences Corporation | $769.88 | 2025 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Cvrx, INC. | $98.26 | 2024 | Barostim Neo System |
| Abiomed | $82.62 | 2019 | |
| Janssen Pharmaceuticals, INC | $53.25 | 2019 | |
| Melinta Therapeutics, LLC | $48.00 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $33.90 | 2019-2020 | |
| Sumitomo Pharma America, INC. | $25.41 | 2023 | Gemtesa |
| Portola Pharmaceuticals, LLC | $19.89 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $10.48 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mehul Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.